Vector Oncology chosen as Actinium’s CRO partner in PhII cancer trial

Actinium Pharmaceuticals ($ATNM) has partnered up with Memphis, TN-based CRO Vector Oncology to help it with a midstage study of its experimental blood cancer med Actimab-A.

The second phase of testing comes after the biotech recently finishes off its small Phase I in 18 older patients with newly diagnosed acute myeloid leukemia (AML).

Phase II will focus on the highest doses used in its first studies along with more patients, 53 in total, in an open-label test. The trial is slated to start later this year, with interim data to be posted halfway through 2017, according to a statement from both companies.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

 “We are delighted to be working with Vector Oncology for our upcoming Phase II clinical trial,” stated Dragan Cicic, Actinium’s CMO.

“Vector Oncology displayed an expertise in hematology clinical trials with an emphasis on Phase II studies, which gives us great confidence in our selection. We look forward to working with Vector Oncology and to benefiting from their robust clinical capabilities.”

Sean Hart, EVP and MD at Vector Oncology, said: “Vector Oncology is excited to be working with Actinium as a member of this important team. Since our first interaction with Actinium, all team members involved have committed to getting this important product in the hands of oncology professionals as soon as possible to advance the research efforts. We very much look forward to an exciting future together.” 

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.